Eli Lilly and Company

Nicolas Jacques Francois Dreyfus

Leonard Larry Winneroski, Jr

Jose Eduardo Lopez

Eric Michael Woerly

Peter James Lindsay-Scott

Sandra Ann Filla

Magnus Wilhelm Walter

Richard Edmund Rathmell

Anette Margareta Johansson

Eric George Tromiczak

Jikesh Arvind Shah

Andrew Faller

Thierry J Masquelin

Peter James Lindsay-scott

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimers disease.

5-methyl-4-fluoro-thiazol-2-yl compounds

The present invention provides a compound of Formula I: wherein R is H or F; or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases, such as Alzheimer's disease. 

2,3-dihydrofuro[2,3-b]pyridine compounds

The present invention provides a compound of Formula I:  or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimer's disease.

6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds

6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.

5-methyl-1,3,4-oxadiazol-2-yl compounds

5-methyl-1,2,4-oxadiazol-3-yl compounds

A serotonin and norepinephrine reuptake inhibitor of the formula: its uses, and methods for its preparation are described.

Serotonin and norepinephrine reuptake inhibitor

Growing community of inventors

Surrey, United Kingdom

Nicolas Jacques Francois Dreyfus